Stem Cells In-Depth Focus 2018
Posted: 31 May 2018 | Drug Target Review | No comments yet
In this issue: urine-derived stem cells offer an innovative platform for drug testing and disease modelling, a paradigm shift in translational stem cell research, and the role of biomaterials in stem cell-based regenerative medicine.
- Urine-derived stem cells as innovative platform for drug testing and disease modelling
Urine-derived stem cells offer an innovative platform for drug testing and disease modelling, writes Lucas-Sebastian Spitzhorn, Shaifur Rahman, Lisa Nguyen, Audrey Ncube, Martina Bohndorf, Wasco Wruck and James Adjaye. - From fibroblasts to medicinal signalling cells: a paradigm shift in translational stem cell research
There’s been a paradigm shift in translational stem cell research from fibroblasts to medicinal signalling cells, according to Jonathan Sheard, Thamil Selvee Ramasamy and Darius Widera. - The role of biomaterials in stem cell-based regenerative medicine
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success, claims Laura Goldie.
This In-Depth Focus is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Analytical techniques, Cell Regeneration, Stem Cells
Related organisations
Essen BioScience, Takara Bio